ADIAL PHARMACEUTICALS INC (ADIL) Fundamental Analysis & Valuation

NASDAQ:ADIL • US00688A3041

Current stock price

1.57 USD
+0.01 (+0.64%)
At close:
1.55 USD
-0.02 (-1.27%)
After Hours:

This ADIL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ADIL Profitability Analysis

1.1 Basic Checks

  • ADIL had negative earnings in the past year.
  • ADIL had a negative operating cash flow in the past year.
  • In the past 5 years ADIL always reported negative net income.
  • In the past 5 years ADIL always reported negative operating cash flow.
ADIL Yearly Net Income VS EBIT VS OCF VS FCFADIL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5M -10M -15M

1.2 Ratios

  • ADIL has a worse Return On Assets (-119.54%) than 80.31% of its industry peers.
  • ADIL has a Return On Equity of -151.19%. This is in the lower half of the industry: ADIL underperforms 70.47% of its industry peers.
Industry RankSector Rank
ROA -119.54%
ROE -151.19%
ROIC N/A
ROA(3y)-163.12%
ROA(5y)-194.3%
ROE(3y)-200.35%
ROE(5y)-308.49%
ROIC(3y)N/A
ROIC(5y)N/A
ADIL Yearly ROA, ROE, ROICADIL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K

1.3 Margins

  • ADIL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADIL Yearly Profit, Operating, Gross MarginsADIL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. ADIL Health Analysis

2.1 Basic Checks

  • ADIL has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for ADIL has been increased compared to 5 years ago.
  • ADIL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ADIL Yearly Shares OutstandingADIL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200K 400K 600K 800K 1M
ADIL Yearly Total Debt VS Total AssetsADIL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M

2.2 Solvency

  • Based on the Altman-Z score of -20.91, we must say that ADIL is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -20.91, ADIL is not doing good in the industry: 86.01% of the companies in the same industry are doing better.
  • There is no outstanding debt for ADIL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -20.91
ROIC/WACCN/A
WACCN/A
ADIL Yearly LT Debt VS Equity VS FCFADIL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M -10M

2.3 Liquidity

  • ADIL has a Current Ratio of 4.42. This indicates that ADIL is financially healthy and has no problem in meeting its short term obligations.
  • ADIL has a better Current ratio (4.42) than 61.14% of its industry peers.
  • ADIL has a Quick Ratio of 4.42. This indicates that ADIL is financially healthy and has no problem in meeting its short term obligations.
  • ADIL's Quick ratio of 4.42 is fine compared to the rest of the industry. ADIL outperforms 63.21% of its industry peers.
Industry RankSector Rank
Current Ratio 4.42
Quick Ratio 4.42
ADIL Yearly Current Assets VS Current LiabilitesADIL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. ADIL Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 62.74% over the past year.
EPS 1Y (TTM)62.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, ADIL will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.19% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y62.78%
EPS Next 2Y33.63%
EPS Next 3Y24.99%
EPS Next 5Y15.19%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ADIL Yearly Revenue VS EstimatesADIL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2030 2031 2032 2033 50M 100M 150M
ADIL Yearly EPS VS EstimatesADIL Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -500 -1K -1.5K

More info and screens

Find the best growth stocksShow best growing peers

1

4. ADIL Valuation Analysis

4.1 Price/Earnings Ratio

  • ADIL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ADIL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADIL Price Earnings VS Forward Price EarningsADIL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADIL Per share dataADIL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

  • ADIL's earnings are expected to grow with 24.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.63%
EPS Next 3Y24.99%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ADIL Dividend Analysis

5.1 Amount

  • ADIL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ADIL Fundamentals: All Metrics, Ratios and Statistics

ADIAL PHARMACEUTICALS INC

NASDAQ:ADIL (4/10/2026, 8:05:06 PM)

After market: 1.55 -0.02 (-1.27%)

1.57

+0.01 (+0.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-05
Earnings (Next)05-12
Inst Owners9.91%
Inst Owner Change-100%
Ins Owners0.32%
Ins Owner Change6.06%
Market Cap2.25M
Revenue(TTM)N/A
Net Income(TTM)-7.98M
Analysts82.22
Price Target23.8 (1415.92%)
Short Float %5.69%
Short Ratio0.31
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.88%
Min EPS beat(2)-40.21%
Max EPS beat(2)43.98%
EPS beat(4)3
Avg EPS beat(4)16.46%
Min EPS beat(4)-40.21%
Max EPS beat(4)43.98%
EPS beat(8)5
Avg EPS beat(8)-0.18%
EPS beat(12)7
Avg EPS beat(12)9.02%
EPS beat(16)10
Avg EPS beat(16)11.74%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-10.26%
PT rev (3m)976.91%
EPS NQ rev (1m)12.79%
EPS NQ rev (3m)-2150%
EPS NY rev (1m)35.04%
EPS NY rev (3m)-1612.55%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.43
P/tB 0.43
EV/EBITDA N/A
EPS(TTM)-18.07
EYN/A
EPS(NY)-6.73
Fwd EYN/A
FCF(TTM)-4.54
FCFYN/A
OCF(TTM)-4.54
OCFYN/A
SpS0
BVpS3.69
TBVpS3.69
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -119.54%
ROE -151.19%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-163.12%
ROA(5y)-194.3%
ROE(3y)-200.35%
ROE(5y)-308.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.42
Quick Ratio 4.42
Altman-Z -20.91
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)62.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64.91%
EPS Next Y62.78%
EPS Next 2Y33.63%
EPS Next 3Y24.99%
EPS Next 5Y15.19%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y5.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y6.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.21%
OCF growth 3YN/A
OCF growth 5YN/A

ADIAL PHARMACEUTICALS INC / ADIL Fundamental Analysis FAQ

What is the fundamental rating for ADIL stock?

ChartMill assigns a fundamental rating of 2 / 10 to ADIL.


Can you provide the valuation status for ADIAL PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 1 / 10 to ADIAL PHARMACEUTICALS INC (ADIL). This can be considered as Overvalued.


Can you provide the profitability details for ADIAL PHARMACEUTICALS INC?

ADIAL PHARMACEUTICALS INC (ADIL) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for ADIL stock?

The Earnings per Share (EPS) of ADIAL PHARMACEUTICALS INC (ADIL) is expected to grow by 62.78% in the next year.